Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples